TF
HZNP

Tompkins Financial’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Tompkins Financial’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$11.6K – 685
2023
Q3 		$11.6K Hold
100
– – ﹤0.01% 455
2023
Q2 		$10.3K Hold
100
– – ﹤0.01% 474
2023
Q1 		$10.9K Hold
100
– – ﹤0.01% 482
2022
Q4 		$11K Hold
100
– – ﹤0.01% 476
2022
Q3 		$6K Sell
100
-200
-67% -$14K ﹤0.01% 516
2022
Q2 		$24K Buy
+300
New +$28.4K ﹤0.01% 398

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Tompkins Financial's HZNP Position: Q4 2023 in Review

Tompkins Financial sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 100 shares — an estimated $11.6K sold.

Tompkins Financial first reported a position in HZNP in Q2 2022 and held it in 6 quarters. The position peaked at $24K in Q2 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Tompkins Financial reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Tompkins Financial sold 100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $11.6K.
  • Tompkins Financial first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 6 quarters.
  • Tompkins Financial's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $24K in Q2 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Tompkins Financial's 13F filing for Q4 2023, filed 8 Jan 2024.